Healthcare Industry News: tyrosine kinase inhibitor
News Release - May 29, 2007
SuperGen Names Gregory Berk, M.D., Chief Medical OfficerDUBLIN, Calif., May 29 (HSMN NewsFeed) -- SuperGen Inc. (Nasdaq: SUPG ) today announced the addition of Gregory Berk, M.D., to the management team as Chief Medical Officer.
Dr. Berk, 49, will lead SuperGen's international clinical development strategy, operations and safety divisions to rapidly advance the company's oncology drug portfolio toward commercialization. His responsibilities will include the design and execution of clinical trials, such as the recently announced Phase I study of MP470, SuperGen's multi-targeted tyrosine kinase inhibitor.
"As we continue to expand our proprietary oncology portfolio, Greg's clinical vision and leadership, and his extensive medical and research experience, will enable our Company to rapidly and efficiently advance each new candidate through clinical development," said James S. Manuso, Ph.D., Chairman, President and CEO of SuperGen.
An oncology veteran with more than 23 years of experience, Dr. Berk was most recently Senior Vice President and Chief Medical Officer for Hana Biosciences, a San Francisco-based oncology company. Previously, he was Medical Director for the Network of Medical Communications and Research, a consulting and medical education company focused on clinical-stage oncology research. Dr. Berk was an attending physician in the Department of Medicine at New York Presbyterian Hospital (Cornell Campus) and an Assistant Professor of Medicine at the Weill Medical College of Cornell University, where he was an investigator in numerous oncology clinical trials, including the pivotal trials for Gleevec as well as colorectal and breast cancer trials for Avastin and a number of CALGB studies.
Dr. Berk holds a medical degree from Case Western Reserve University School of Medicine in Cleveland, Ohio. He began his undergraduate studies in biochemistry at Cambridge University in Cambridge, England and graduated summa cum laude from Tulane University in New Orleans, La. Dr. Berk completed his internship, residency and fellowship at The New York Hospital -- Cornell Medical Center. He is Board certified in internal medicine and medical oncology and is a member of the American Society of Hematology and the American Society of Clinical Oncology.
Based in Dublin, Calif., SuperGen is a pharmaceutical company dedicated to the discovery, rapid development and commercialization of therapies for solid tumors and hematological malignancies. SuperGen is developing a number of therapeutic anticancer products focused on kinase inhibitors and DNA methyltransferase. For more information about SuperGen, please visit http://www.supergen.com
This press release contains "forward-looking" statements within the meaning of Section 21A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and is subject to the safe harbor created thereby. The actual results could differ materially from those projected in the forward-looking statements as a result of a number of risks and uncertainties. These forward-looking statements include statements regarding the ability of our products to enter clinical trials and the potential validation of our discovery process to produce new compounds. SuperGen's products may not enter clinical trials and even if these products do enter clinical testing there is no assurance that these tests will be successful. Additionally, the early successes in preclinical work may not be a validation of our discovery process and past success may not predict future success. Other factors that could cause actual results to differ materially from expectations include, but are not limited to, the risk factors detailed in the Company's filings with the Securities and Exchange Commission including reports on its most recently filed Form 10-K and Form 10-Q. These forward- looking statements are made only as of the date hereof, and we disclaim any obligation to update or revise the information contained in any such forward- looking statements, whether as a result of new information, future events or otherwise.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.